投资组合

Engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera's single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a unique combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation.

Biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates. With an initial focus on immunology, ACELYRIN is targeting both early-stage innovation as well as clinical-stage programs where it can leverage its expertise to rapidly advance medicines to patients.

Acutus is working to develop a novel electro-anatomical mapping catheter for atrial fibrillation ablation procedures. The Acutus system integrates ultrasound technology and a proprietary dipole density mapping technology to generate a three dimensional image of the left atrium over which the electric activity of the chamber can be precisely displayed in real time.

A commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases.

Clinical stage company developing first-in-class ADCs for the treatment of cancers. Lead program (ADCE-T02) targets tissue factor with an antibody designed for minimized interference with the coagulation pathway, reducing the risk of bleeding. ADCE-T02 uses a clinically validated linker-payload platform designed for improved bystander activity and linker stability

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. The company’s genome-wide methylation analysis technology has the unique ability to distinguish the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially target those informative regions for sequencing.

Adicet Bio, Inc., is developing a novel universal immune-cell therapy platform for cancer and other disease indications and novel immunotherapies directed to disease-specific targets derived from the intracellular proteome.

Advanced Enzymes is a leading enzyme company in India with a portfolio of over 400 unique enzyme products.

Developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs

Aerin Medical is developing non-invasive procedures for the treatment of chronic nasal airway conditions. The company’s FDA-cleared products, the VivAer® Stylus for nasal airway obstruction and the RhinAer® Stylus for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with a nonsurgical procedure under local anesthetic in their offices.

AIMS (Asian Institute of Medical Sciences) Hospital is one of the leading multi-specialty hospital chains in North India with a growing presence in East India. The Company has a network of 6 hospitals across Tier 2 and 3 cities.

Alentis is a clinical stage biotech company developing first-in-class ADCs and antibodies targeting Claudin-1 for the treatment of solid tumors and fibrosis

Aliada is developing a platform to improve drug delivery to the brain for multiple modalities including, monoclonal antibodies, enzymes, and oligonucleotides

Alpheus™ Medical, Inc., is developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers. The company's lead product utilizes a novel, non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).

Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. The company is led by seasoned R&D leaders with a history of developing marketed oncology small molecule drugs.

Amolyt Pharma developing two therapeutic peptides for rare endocrine and metabolic diseases AZP-3601, a conformation specific PTH analogue, an analog of IGFBP2, a key regulator of fat, glucose and bone metabolism for glucose control in rare genetic Lipodystrophies and insulin receptor-opathies.

Biotechnology company advancing novel therapies to address the needs of patients with immunological and inflammatory disorders. Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways

Arcatron is a consumer medical company offering mobility assist devices like wheelchairs for patients with limited mobility and orthopedic body supports for pain relief and comfort enhancement. Arcatron follows an online-first marketing approach and sells its products across its own D2C website, online marketplaces, and offline channels.

ArriVent is a clinical-stage drug development platform company focusing on identifying, licensing and unlocking the global value of top biotech innovations from China into the U.S. The company has in-licensed multiple assets of various modalities including small molecules, large molecules, ADCs, etc.

ARS is developing treatments for patients and parents affected by severe allergic reactions that are safe and effective, needle-free, easy to carry, and simple to administer

Asceneuron is a clinical stage biotech company developing orally bioavailable therapeutics targeting tau protein aggregation for the treatment of neurodegenerative diseases.

Aspen Neuroscience is focused on developing induced pluripotent stem cells to treat neurological conditions.

Clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases

Developing the next generation of oncology therapies for patients

A regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL System technology platform, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects and for repigmentation of stable depigmented vitiligo lesions, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin cells.

Avitide develops customized biopharmaceutical affinity purification products. The Avitide platform reduces bioprocess development timelines, program risk, and cost of manufacture by providing turnkey, cost-effective, highly specific affinity purification solutions. Industry-leading affinity resin discovery timelines integrate seamlessly into process development cycles, providing improved line-ofsight, platform operations and equipment, and predictable scalability.

Azura Ophthalmics is a clinical-stage biotechnology company headquartered in Tel Aviv-Yafo, Israel. Azura Ophthalmics is developing an innovative portfolio of compounds – in combination with a novel drug delivery platform – to advance treatments for lid margin diseases such as Meibomian gland dysfunction (MGD), the leading cause of dry eye disease.

binx io is a first-of-its-kind, highly sensitive and specific, point-of-care (POC) diagnostic testing platform and is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)– the two most tested-for STIs globally.

Clinical-stage company developing an oral small molecule apelin receptor agonist for obesity, with a focus on improving the quality of weight loss through muscle preservation.

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D. and biotech veteran, Y. Peter Li, Ph.D., M.B.A.

BMTfemme is commercializing an AI-powered portable colposcope, enabling primary care providers to perform specialist-level visual diagnosis of gynecological conditions.

Advanced laser-based intravascular lithotripsy (IVL) platform that delivers consistent acoustic output to treat calcification across variety of vessel beds.

CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.

Candid Therapeutics is an innovative biotechnology company dedicated to advancing T cell engagers for the treatment of immunological diseases. Established in 2024 and headquartered in San Diego, CA, Candid is driven by a team of repeatedly successful entrepreneurs with deep expertise and strong execution abilities. Supported by a distinguished syndicate of leading healthcare investors, Candid is committed to discovering and developing cutting-edge therapeutic programs that address significant unmet medical needs in immunology.

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to develop new treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. The Company was co-founded by pioneers in the field of CAR-based immunotherapy, nucleic acid drug delivery, tLNPs, and regenerative medicine, including experienced industry leaders, as well as academic faculty members from the University of Pennsylvania. Capstan has a bicoastal presence with operations in San Diego, CA and Philadelphia, PA.

A leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease.

Carrot Fertility is a global fertility benefits provider for employers, built to support employees as they navigate the fertility journey by offering financial benefit and high-touch support. Companies use Carrot to customize a fertility benefit that provides employees financial, medical, and emotional support as they pursue parenthood.

Cellipont Bioservices is a privately held cell therapy CDMO operating in The Woodlands, TX with more than 15 years of experience in the development and manufacturing of cell therapies, ranging from small to large-scale batches. Cellipont has deep technical expertise and has been recognized by customers and partners for its ability to productively grow challenging cell types.

CHARM Therapeutics is applying its end-to-end 3D deep learning protein-ligand co-folding technology, DragonFold, to develop small molecule therapeutics against previously hard-to-drug targets in cancer and other therapeutic areas

Chemomab is developing novel chemokine blocking therapies for inflammatory and fibrotic disorders

Compass Therapeutics is seeking to cure various cancer types through combination therapy by comprehensively drugging the tumor-immune synapse with human antibodies against over 50 cell surface and soluble targets

Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Using structural bioinformatics, computational chemistry, and machine learning, the Company is deploying an in-silico platform that enables the design of new pharmacological stabilizers, a validated class of small molecules, at an unprecedented speed and scale.

Clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate cancer

Corteria is a Sanofi spin out developing long acting corticotrophin release factor type 2 receptor (CRF2) agonists to overcome the limitations of short half-life urocortin analogs for use in heart failure.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. Using both small molecule and monoclonal antibody approaches, Corvus brings together scientists who played key roles in the development of Rituxan, Imbruvica, and Zelboraf to advance new immuno-oncology therapeutics.

Crinetics Pharmaceuticals is a clinical-stage biotechnology company focusing on treatments for rare endocrine disorders and endocrine-related cancers. The company is currently conducting a Phase 3 trial with its oral somatostatin agonist, Paltusotine, for the treatment of acromegaly, an orphan disease affecting more than 24,000 people in the United States. The company is also developing other oral somatostatin agonists for neuroendocrine tumors, hyperinsulinism, and chronic pain, as well as an oral small molecule for Cushing’s disease.

Cullinan Therapeutics is built to develop a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. The company's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class.

Cyrus Biotechnology is a privately-held biotechnology software company offering protein modeling and design capabilities to the biopharmaceutical, chemical, consumer products and synthetic biology industries. The company was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of biologics and small molecules.

Delfi Diagnostics is developing a new class of high performance, affordable liquid biopsy tests for early cancer detection. Leveraging recent advances in cancer biology and machine learning, Delfi’s technology can achieve high performance from low-cost, widely available sequencing technology.

Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic disorders. Disc Medicine is building a unique portfolio of innovative, first-in-class therapeutic candidates based on fundamental pathways of red blood cell biology.

Edgewise Therapeutics builds on our extensive experience in drug development and skeletal muscle research. Edgewise has built a custom discovery workshop for the discovery and optimization of novel therapeutics for a broad set of indications where skeletal muscle function is compromised.

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and depletes pathological immune cells.

EnLiven Therapeutics is a targeted oncology company developing small molecule kinase inhibitors. Enliven’s approach combines clinically validated biological targets and industry-leading chemistry to design best-in-class and first-in class therapies to address unmet needs in cancer.

Entero is one of the largest pharmaceutical and medical device distribution companies in India. It has an extensive customer base of retail pharmacies and hospitals. Entero distributes products for most of the leading companies in the country through its pan-India network of state-of-the-art warehouses and technology infrastructure.

ENYO Pharma is a clinical stage biotech with a unique drug discovery engine inspired by viruses. The company is currently entering Phase 2 with its lead compound Vonafexor in Alport Syndrome.

Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that drive the production of therapeutic proteins within patients’ cells and tissues. The company’s lead program ETH42 is in preclinical development for treatment of a rare pulmonary disease, primary ciliary dyskinesia.

Eurolife Healthcare manufactures and distributes a portfolio of healthcare formulations, intravenous infusions, ophthalmics, and sterilized water for injections. They have manufacturing facilities in India and Hungary (EU-GMP approved).

Evox Therapeutics is a biotechnology company focused on improving the natural delivery capabilities of exosomes. Evox has developed a proprietary technology platform, DeliverEX, to enable it to modify exosomes, to load drugs into exosomes, and to target the delivery of these exosomes to organs of interest.

Evozyne creates novel protein systems that enable a healthier world.

Developing mRNA-encoded genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases in a redosable format

A personalized medicine diagnostics company assessing the activity of mutations and combination of mutations and their response to targeted drugs

Forsight Vision 6 is developing an Accommodating Interocular Lens (AIOL) which aims to enable pristine vision across all distances post cataract surgery. The approach is differentiated, placing the lens over rather than in the capsular bag, thereby avoiding the stiffening which hinders accommodation. Founders and leadership are composed of world class ophthalmology veterans.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate for potentially broad autoimmune and autoimmune-related indications.

Forward Therapeutics is a biopharmaceutical company dedicated to transforming the treatment of chronic inflammatory disorders.

Fusion is a clinical-stage biopharmaceutical company with the goal of treating cancer by developing targeted alpha therapeutics. Fusion is exploiting its unique expertise in linking medical isotopes to targeting molecules, via its proprietary Fast-ClearTM Technology Platform, to create highly effective therapeutics.

FUSmobile is developing a handheld focused ultrasound device, addressing pain non-invasively, with initial focus on back pain.

At FutuRx, Johnson & Johnson Innovation - JJDC, Takeda Ventures Inc. and OrbiMed Israel Partners teamed with the Office of the Chief Scientist of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines. FutuRx envisions its role as a catalyst for drug development by bridging the gap between concept and proof-of-concept through its dedicated system and unique structure

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases. As the industry’s first off-the-shelf offering, Garuda’s technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells.

Gennao Bio is a genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio’s proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics.

GliXogen Therapeutics is developing novel inhibitors of the transcription factor Gli1 to enhance remyelination in demyelination indication such as multiple sclerosis. Inhibition of Gli1 results in robust differentiation of neural stem cells into remyelination oligodendrocytes which migrate to white matter lesion sites and generate functional myelin. GliXogen have identified highly potent, orally bioavailable and brain penetrant molecules which have shown impressive in vivo efficacy in several demyelinating models and are now in lead optimization stages.

The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.

A mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. iECURE’s approach focuses on the in vivo insertion of healthy copies of disease-causing genes, with an initial focus in liver disorders.

Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.

ImmPACT-Bio is developing a novel Chimeric Antigen Receptor T-cell (CAR-T) strategy that uniquely differentiates cancerous from non-cancerous tissues, and specifically addresses a common mechanism, loss of allelic heterozygosity (LOH), for tumor immune-escape. Our approach will expand the target repitiore for CAR T therapies in solid tumors. The company was founded at the FutuRx incubator based on the research of Prof. Gideon Gross, an early leader in immunogene therapy who invented the first CAR in Zelig Eshhar’s lab at the Weizmann Institute.

Innvolution focuses on interventional cardiology with a comprehensive portfolio of products including imaging equipment and consumables. It is the largest indigenous manufacturer and supplier of Catheterization Laboratories (Cath Labs) in India. The company has a strong pan-India distribution network with multiple touchpoints across hospitals and interventional cardiologists.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan.

InspireMD is a commercial-stage medical device company developing novel carotid stent technologies with integrated embolic prevention systems (EPS) to deliver neurovascular protection and stroke prevention.

Invivyd is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. The company’s candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect.

Janux Therapeutics is developing novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets and can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Kapiva is a leading health and wellness-focused consumer company marketing natural and Ayurveda products to the 20-45-year age group. The Company offers products for men’s health, skin and hair, weight management, lifestyle diseases, and daily wellness. Kapiva has an omnichannel distribution with a digital-first approach and is emerging as a leader amongst the direct-to-consumer natural and Ayurveda companies in India.

Kartos Therapeutics is a clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta, or TGF-beta, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone.

Kinnate Biopharma is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities.

Kumquat’s mission is to develop innovative therapies to bring about sustainable and life-changing benefits to cancer patients.

Laxmi Dental is a leading dental products and lab services company offering crowns, bridges, aligners, and pediatric products for domestic and export markets. The Company has a global reach and caters to a large network of dentists in India, the USA, and Europe.

Developing novel therapeutics for patients with major disorders of the central nervous system

LifeCell is an established and trusted consumer healthcare services brand focused on maternal and child health. The Company operates India’s largest cord blood bank and is an emerging leader in the fast-growing reproductive diagnostics segment. The Company also offers placental tissue-based products that support the healing of chronic wounds.

Medical device company developing self-expanding percutaneous mechanical circulatory support pumps intended to provide minimally-invasive support to the native heart during acute episodes of dysfunction.

Marksans Pharma Limited is engaged in manufacturing, research and marketing of generic pharmaceutical formulations globally. Key focus areas are OTC and prescription (Rx) drugs across various therapeutic categories such as Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic.

MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases. MBX is strengthened by world-class proprietary peptide drug discovery capabilities.

MDClone was founded to address one of the most critical bottle necks in the healthcare market by creating synthetic medical records, based on real data with interactive anonymization. Allowing for greater utilization of existing medical data in a manner that does not infringe on patients' privacy

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases.

Memebox has a diverse portfolio of clean beauty and hypoallergenic brands including I Dew Care, Kaja, Nooni, Pony Effect, I'm Meme.

MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.

Mirador Therapeutics envisions a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and better development accuracy.

NeRRe Therapeutics is a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity. The company was formed in December 2012 and is focused on the development of a portfolio of NK receptor antagonists acquired from GlaxoSmithKline, which have therapeutic potential in a broad range of indications.

A commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need.

Neurogastrx is a biopharmaceutical company focused on discovering and developing transformative therapies for gastrointestinal disorders affecting the enteric nervous system.

NeuroPace is a commercial-stage medical device company that markets the Responsive Neurostimulation (RNS) System for medically refractory epilepsy with 1 or 2 epileptogenic foci. The RNS System continually monitors brainwaves for unusual activity and is able to respond instantly with corrective stimulation, thereby reducing seizure frequency; it is the first and only closed-loop responsive neurostimulation system.

NextCure, launched in 2015, is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products

Noctrix Health is a pioneer in developing the next-generation of wearable therapeutics. Backed by scientific evidence and clinical data, it aims to make prescription-grade medical devices accessible so physicians and patients have more choices beyond the pill.

Nucleix develops, manufactures and markets revolutionary non-invasive molecular cancer diagnostic tests. Nucleix's highly sensitive and specific tests are based on identification of subtle changes in methylation patterns

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next generation immunomodulators and oncology medicines. Comprised of an expert team of drug hunters and executives, Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines

OmniGuide, Inc. is a patient safety-focused medical technology innovator, providing a portfolio of advanced energy surgical tools to benefit clinicians and their patients alike. The company’s technologies deliver energy in a precise and electrically silent manner, resulting in the preservation of healthy tissue. OmniGuide Surgical, a leader in flexible fiber CO2 laser technology, offers a range of products designed to enhance surgical accuracy, access, and control for minimally invasive surgery, laparoscopy, and robotic-assisted surgery. Domain Surgical, by OmniGuide, Inc., provides a patented ferromagnetic technology designed to provide safety and predictability in selected surgical procedures that require cutting, coagulating, and sealing of tissue. LISA Laser Products GmbH, a leader in holmium and thulium laser technology, offers a wide range of products focused on improving clinical and patient outcomes in otolaryngology, neuro, and urological surgical procedures.

Dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, including CUSP06, a CDH6 ADC.

Ottimo Pharma is a private biotechnology company focused on the development of cancer therapies for solid tumors. The company’s lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration, and license agreement with the University of Pennsylvania.

Committed to the development of multiple advanced therapeutics that address unmet needs in the management of end-stage kidney disease

Perfuse Therapeutics is a clinical-stage biotechnology company pursuing a novel mechanism to improve retinal perfusion in the context of various retinal diseases, starting with glaucoma.

PIC Therapeutics is focused on fundamentally changing how we treat cancer by discovering and developing first-in mechanism, first-in-class small molecule therapeutics that modulate protein translation.

PMV Pharma is developing first-in-class wildtype and mutant allele-specific p53 modulators for the treatment of cancer.  Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Prelude Therapeutics is a biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer.

Clinical-stage biotechnology company developing a pipeline of multiple antibody-drug conjugate therapeutics targeting solid tumors and hematological malignancies. The Company’s lead ADC program, rinatabart sesutecan, is targeting FRa

Prothelia is a preclinical-stage biopharmaceutical company focused on the development of novel therapeutic proteins to treat rare muscle diseases with extremely high unmet need. Prothelia is initially focusing on patients with LAMA2 deficient congenital MD.

Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.

A global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro-orphan diseases, and oncology.

Committed to realizing the potential of gene therapy to provide safe, long-lasting treatments for a wide range of diseases. Rampart’s versatile approach is driven by proprietary development and delivery platforms, which together create optimized therapeutics in a redosable, non-viral format.

ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. The Company’s diverse pipeline includes lead programs for cystic fibrosis caused by nonsense mutations, and primary ciliary dyskinesia. ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively.

Repare is a clinical-stage precision oncology company using its CRISPR-based SNIPRx® platform to develop and target specific vulnerabilities of tumor cells

Scorpion Therapeutics is a next-generation precision oncology company. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry and translational medicine to deliver Precision Oncology 2.0.

scPharmaceuticals is developing a portfolio of pharmaceutical products for subcutaneous delivery. The company is focused on facilitating the subcutaneous delivery of drugs that currently require intravenous or intramuscular injections via a proprietary patch pump technology.

Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine.

Sikka Software develops cloud platform technologies to enhance practice economics, improve the quality of care and service experience for patients, and provide suppliers with more effective ways to reach clinicians and patients. Sikka focuses on the non-physician, non-hospital healthcare segments, which include dentistry, veterinary, audiology, optometry, and other adjacent markets, both in the US and internationally

Sionna Therapeutics is a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF

Developer of anti-inflammatory medicines for the treatment of neurodegenerative diseases and inflammatory diseases.

Clinical-stage company developing isoform-selective inhibitors of the voltage gated sodium channel for the treatments of pain and other peripheral hypersensitivity disorders.

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular corticosteroids in key tissues.

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients who lack effective treatment options. Star consists of a family of companies, each focused on a specific area of biology with first-in-class therapies that each target multiple diseases.

Suraksha is the leading diagnostics company in Eastern India offering pathology and radiology services. The Company has a strong brand in the region and offers a comprehensive suite of diagnostic tests. Suraksha’s central lab features Eastern India’s largest fully automated robotic track and is accredited by College of American Pathologists (CAP) and National Accreditation Board for Testing and Calibration Laboratories (NABL).

TELA Bio (Nasdaq: TELA) is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA’s products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

Tergus Pharma is an end-to-end service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing.

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets.

Terremoto Biosciences is advancing its lysine-based covalency platform to expand the covalent drug alphabet and develop small molecule medicines for a range of highly complex diseases, including cancer

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. The lead product candidate, THB001, is the first highly selective, oral small-molecule KIT inhibitor to enter clinical development.

Used in over 3,000 facilities, TigerConnect has established itself as the leader in secure messaging for healthcare. From large hospital networks to small private practices, healthcare organizations use TigerConnect as their preferred method of secure communication to comply with HIPAA, HITECH and other industry standards.

Clinical-stage biotech advancing three potential best-in-class assets, including a cap-dependent endonuclease inhibitor for influenza, protease inhibitor for COVID19, and CDK4/6 inhibitor for LGEEC

Treeline Biosciences is a biotechnology company prioritizing molecular targets in oncology that are validated but difficult to drug. Treeline’s mission is to develop a pipeline using its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.

TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors.

Pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of Immunology & Inflammation disorders, including Atopic Dermatitis.

Turnstone Biologics is developing a first-in-class, systemically-administered oncolytic viral immunotherapy that combines a bioselected and engineered Maraba virus to directly lyse tumors with a potent vaccine that drives tumor-antigen specific T-cell responses of unprecedented magnitude

TytoCare provides the missing link in telehealth - a digital examination tool and platform that connects patients at home to clinicians, to better inform their diagnoses. TytoCare expands the range of conditions that can be reliably diagnosed via telehealth by capturing comprehensive physical exam data at home and delivering it to a remote physician.

Upstream Bio is a biotechnology company focused on developing therapeutics that address allergic and inflammatory diseases through upstream targeting

Uquifa is a small molecule CDMO providing development and manufacturing services to originator and generic customers for chemical intermediates and finished Active Pharmaceutical Ingredients (APIs). It has R&D and cGMP manufacturing facilities in Europe, North America, and India.

A specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today and the only single-shot chikungunya vaccine candidate.

Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases. The company’s lead program is focused on developing small-molecule activators of glucocerebrosidase (GCase) that have the potential to treat Parkinson’s disease patients as well as those with Gaucher disease.

Velsera is the precision engine company. Velsera connects healthcare and life sciences to reveal the true promise of precision medicine - a continuous flow of knowledge among researchers, scientists and clinicians around the world, creating insights that radically improve human health. Velsera comprises three global, industry leading organizations in the healthcare and life science industries: Pierian, Seven Bridges, and UgenTec.

Verastem is a late stage development biopharma advancing novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK and FAK inhibition

A dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, Verrica’s lead product, YCANTH™ (cantharidin) (formerly known as VP-102), became the first treatment approved by the FDA to treat pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection affecting approximately six million people in the United States, primarily children

Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II Type 2 Receptor (AT2R) has a central role in stopping and reversing disease pathology.

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. X4’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance.

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant seeks to leverage its resources to successfully compete in global neurological and orthopedic surgery markets.

正腾康是一家位于上海的生物制药企业，致力于开发抗肿瘤疗法。正腾康从Zentalis（NASDAQ: ZNTL）引进了多项临床阶段的项目和研发技术，同时也在开发自有技术，服务中国和全球的肿瘤患者

立足中国、面向全球的创新临床研究机构

中国领先的细胞治疗公司，开发自体和异体的CAR-T 产品，并致力于为患者提供供得起，且疗效经济意义较高的免疫细胞疗法

亿腾医药是中国领先的专业医药公司，致力于将全球优质的药品引入中国医疗市场，业务包括产品引进、推广和营销等。亿腾医药拥有20多个办事处和400多名销售代表，是众多跨国制药公司的首选合作伙伴。

致力于提供运动医学的整体临床解决方案，已有300多个应用于肩关节、膝关节、足/踝关节、髋关节、肘关节、手/腕关节的运动医学设备、植入物和手术器械品规通过国家药监局的批准，临床应用于国内31个省市、自治区的数千家医院，产品远销南美洲、欧洲、非洲、亚太地区。

医思集团是香港最大的非医院医疗服务提供商，专注于预防和精准医学，致力于构建领先的一站式医疗生态系统，使更多人获得健康、美丽和幸福。集团服务涵盖面极广，旗下主要知名服务品牌包括连续多年荣全港第一的一站式医学美容解决方案DRREBORN，及多元化多维度的医学服务。

博能华是中国领先的骨科产品供应商，已有超过15年的骨科行业历史。博能华凭借其世界一流的研发能力，与西方国家的广泛联系，为中国市场带来最先进的技术，是海外厂商进入中国骨科市场的理想合作伙伴。

基准医疗是一家以液体活检技术为平台，同时提供肿瘤的早筛早诊产品以及服务的中国企业。公司开发了多款肿瘤早期诊断以及复发监测产品，涵盖了多种高发肿瘤以及血液和尿液等多种样本类型。

大米和小米是中国专业的孤独症儿童早期干预机构，为孤独症儿童及家庭提供干预康复、融合支持、家长培训及科普咨询等服务

中国领先的集研发、生产、销售市场于一体的实验室通用小型仪器设备公司

奥普生物是中国领先的即时检验公司。公司现在拥有即时检验产品覆盖了感染，妇女健康，心血管和糖尿病等领域，并在中国超过2,000家医院提供相关服务。

中国领先的基层诊所物联网医疗服务提供商，通过建立云平台为基层诊所、药店提供临床检验，药品，特色疗法，以及互联网问诊等服务

中国领先的一家专注于骨骼、肌肉和关节疾病全新药物研发的创业企业

中国领先的神经消融平台公司，开发应用于肺高压，心衰，和高血压的创新疗法

中国领先的神经以及外周介入医疗器械企业，丰富的产品管线覆盖神经血管以及外周血管介入手术的全部核心耗材

德韩口腔是一家中国领先的口腔连锁机构，以武汉为总部， 覆盖周边数个省份，提供国际化的口腔正畸、口腔种植及其他多个重点口腔医学业务。

惠尔医疗专注于研发、生产和销售高科技医疗影像设备。惠尔拥有卓越的管理团队和员工团队，依靠低成本的研发和生产，为客户提供优质产品和服务。

湖南新合新生物是中国领先的甾体药物中间体和原料药供应商，并依靠多年积累的甾体复杂工艺基础将业务拓展至合成生物制造领域，确立了甾体/医药中间体、动保/饲料添加剂、生物农药/农业产品、食保健品、可降解材料等五大战略产业布局。

来凯医药是一家专注于肿瘤和代谢性疾病领域的创新药研发企业，在新一代药物的研发上独树一帜

洋浦晨星是一家总部位于北京的CRO公司。其业务范围包括：小分子API的化学合成以及生产流程开发、剂型研究、生物等效性研究和临床试验。

位于中国的临床阶段的生物医药公司，致力于开发和商业化具有高度未满足临床需求的、针对癌症和其他威胁生命疾病的创新药物

爱康宜诚是中国人工关节植入物领域领军者。公司拥有齐全的骨科生物产品线，覆盖超过2000家医院，500多家经销商。爱康宜诚同时也是中国骨科3D打印技术的先行者。

中国领先的POCT企业，提供一整套心脏以及血型检测所需要的诊断试剂以及仪器

中国领先的生物创新药公司致力于肿瘤药物的开发

益方生物致力于研发具有Best- 和First-in-class的潜力，针对肿瘤、代谢等重大疾病领域的创新药

益杰立科是领先的专注于表观遗传修饰的基因治疗公司，已进入临床研究阶段。公司于2021年由一批引领基因编辑平台技术和基因编辑疗法的科学家成立，拥有多个针对抗病毒、心血管、眼科、神经退行性疾病领域的产品管线。

神络医疗是一个领先的神经调控平台型企业，提供完整的疼痛管理医疗器械产品线以及其他治疗领域的神经调控产品。

四川科瑞德制药股份有限公司是一家专注于中枢神经系统疾病用药的研发、生产和销售于一体的高新技术企业。

中国领先的二尖瓣及主动脉瓣介入治疗器械的研发企业，产品线覆盖经导管二尖瓣置换修复，以及主动脉瓣置换

腾复医疗是一家临床阶段的医疗器械公司，专注于用于静脉血栓栓塞疾病 (VTE) 的介入医疗器械，包括肺栓塞 (PE)、深静脉血栓 (DVT) 和其他相同的疾病血管通路的介入器械等.

腾迈医药是一家致力于重塑药物分子发现平台的科技公司。该公司将专有的基于量子力学及人工智能驱动的高性能计算平台与规模化高效湿实验室相结合，以提供一站式解决方案。腾迈医药在快速构建其网络化的高性能计算平台和算力，来帮助全球的合作伙伴提高药物分子发现速度，降低研发成本。

位于中国中部地区领先的眼科连锁医院。艾格眼科设立包括白内障、屈光手术及小儿眼病等共十大诊疗科目，为广大眼疾患者提供全面、专业、系统的诊疗服务。

中美领先的基因治疗公司致力于为中国患者提供高质量且负担得起的基于重组腺相关病毒载体的基因治疗产品

英矽智能通过人工智能辅助药物开发，有效降低成本，提高药物研发成功率。英矽智能持续在早期药物研发，AI软件迭代进行突破，并具有多个小分子药物的管线

蝶和科技立志成为康复及运动医学（RSM）、智能药品管理与供应（IMS）中技术与应用平台中的佼佼者，致力于改善患者运动功能的恢复，提升医院药品使用及管理的安全性与有效性。蝶和科技富于激情的工作团队遍布全球。

赞荣医药是一家处于临床阶段，致力于小分子肿瘤创新药物研发的生物科技企业。成立于2018年，在上海和苏州分别设立研发部门。 针对大量未满足的临床需求, 赞荣医药运用自己在DMPK方面的优势，设计和开发有差异化的“best-in-class”和“first-in-class”的药物。公司由拥有跨国药企多年新药研发经验的管理者创立。目前有多个具有自主知识产权的在研项目逐渐推进至临床阶段。

锦欣福星康养是中国领先的养老综合服务运营商。公司集机构、居家、社区三位一体发展的护理模式，以“全方位医养结合”为核心，提供包含健康管理、生活照料、基本医疗、老年康复、专业护理等全老年生命周期健康照护服务。 公司计划深耕川渝、长三角、大湾区为首三大核心区域，同时向外拓展完成全国养老产业布局。

阶梯医疗是侵入性脑机接口（BCI）领域中专注于独有技术平台和产品开发的领导者。该公司专注于为神经科学研究和临床应用开发产品，其中临床应用重点关注运动功能障碍和神经退行性疾病。

靖因药业成立于2021年，是一家国际创新的生物技术公司，聚焦新一代核酸创新疗法在心血管疾病领域的开发。公司成立于2021年，由全球知名的医疗健康投资机构孵化，并拥有国际卓越的管理团队。公司拥有自主知识产权的小核酸药物研发的核心技术平台，并打造了多个具有同类首创和同类最佳的差异化全球竞争优势的产品管线。

高视是中国最大的眼科医疗器械公司之一，同时拥有代理和自有产品业务。